As of the 25th April 2022, Deepbridge Capital is proud to announce that it has deployed a record £31.5 million into early-stage technology and life sciences companies during the 2021/22 tax year, up from £29.4 million in 2020/21.
GenoME Diagnostics, an investee company within Deepbridge's Life Sciences SEIS portfolio has recently won a £50,000 award that is to be given to Shannon Beattie (CEO - GenoME Diagnostics) as part of the celebrations marking International Women’s Day on March 8th 2022, which will be used to aid early detection of ovarian cancer.
FluoretiQ, which is part of the Deepbridge Life Sciences EIS portfolio, as of February 21st 2022, has announced the completion of a £1.1 million, pre-series A investment. The funding round was led by Deepbridge Capital, with significant participation from MAINStream, OION, SAIC and existing investors.
Deepbridge Capital has been shortlisted for the Deal of the Year (Transaction size below £2.5 million) Award at the upcoming 2022 Insider Media, Northern Ireland Dealmakers Awards.
The 2022 Northern Ireland Dealmakers Awards will be honouring the achievements of the highly committed professional corporate finance community, which has supported businesses across Northern Ireland over the last 12 months.
Deepbridge Capital has deployed over £50 million of capital into UK life sciences companies.
The Deepbridge Life Sciences EIS was launched in 2017 as our first life sciences focused EIS fund, providing private investors with access to a portfolio of early-stage investee companies across the biopharmaceutical, biotechnology, medical technology and digital healthcare sectors.